BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27458170)

  • 1. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
    Zou Y; Ma X; Yu H; Hu C; Fan L; Ran X
    Oncotarget; 2017 Jun; 8(24):39805-39817. PubMed ID: 27458170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
    Mushtaq A; Iftikhar A; Hassan H; Lakhani M; Sagar F; Kamal A; Zahid U; Ali Z; Razzaq F; Zar MA; Hassan SF; Safdar A; Raychaudhuri S; Anwer F
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):447-461. PubMed ID: 31060991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
    Del Giudice ML; Gozzetti A; Antonioli E; Orciuolo E; Ghio F; Ciofini S; Candi V; Fontanelli G; Attucci I; Formica G; Bocchia M; Galimberti S; Petrini M; Buda G
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577823
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
    Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
    Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
    Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
    Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
    Perrot A; Delimpasi S; Spanoudakis E; Frølund U; Belotti A; Oriol A; Moreau P; McFadden I; Xia Q; Arora M; Dimopoulos MA
    Leuk Lymphoma; 2024 Jun; 65(6):833-842. PubMed ID: 38497533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
    Sheng Z; Li G; Li B; Liu Y; Wang L
    Eur J Haematol; 2017 Jun; 98(6):601-607. PubMed ID: 28295593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
    Chen CC; Parikh K; Abouzaid S; Purnomo L; McGuiness CB; Hussein M; Wade RL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
    Dechow T; Aldaoud A; Behlendorf T; Knauf W; Eschenburg H; Groschek M; Hansen R; Söling U; Grebhardt S; Siebenbach HU; Vannier C; Potthoff K
    Eur J Haematol; 2022 Feb; 108(2):133-144. PubMed ID: 34714555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
    Leleu X; Karlin L; Macro M; Hulin C; Garderet L; Roussel M; Arnulf B; Pegourie B; Kolb B; Stoppa AM; Brechiniac S; Marit G; Thielemans B; Onraed B; Mathiot C; Banos A; Lacotte L; Tiab M; Dib M; Fuzibet JG; Petillon MO; Rodon P; Wetterwald M; Royer B; Legros L; Benboubker L; Decaux O; Escoffre-Barbe M; Caillot D; Fermand JP; Moreau P; Attal M; Avet-Loiseau H; Facon T;
    Blood; 2015 Feb; 125(9):1411-7. PubMed ID: 25575538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
    Fouquet G; Karlin L; Macro M; Caillot D; Roussel M; Arnulf B; Pegourie B; Petillon MO; Mathiot C; Hulin C; Kolb B; Stoppa AM; Brechiniac S; Rodon P; Dib M; Tiab M; Richez V; Araujo C; Wetterwald M; Garderet L; Royer B; Perrot A; Benboubker L; Decaux O; Escoffre-Barbe M; Fermand JP; Moreau P; Avet-Loiseau H; Attal M; Facon T; Leleu X
    Ann Hematol; 2018 May; 97(5):831-837. PubMed ID: 29330561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
    Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F
    Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
    Kawaji-Kanayama Y; Kobayashi T; Muramatsu A; Uchiyama H; Sasaki N; Uoshima N; Nakao M; Takahashi R; Shimura K; Kaneko H; Kiyota M; Wada K; Chinen Y; Hirakawa K; Fuchida SI; Shimazaki C; Matsumura-Kimoto Y; Mizutani S; Tsukamoto T; Shimura Y; Horiike S; Taniwaki M; Kuroda J;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1476. PubMed ID: 34124862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
    Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A;
    Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.